{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T18:21:45Z","timestamp":1790965305407,"version":"4.1.0"},"reference-count":9,"publisher":"Oxford University Press (OUP)","issue":"12","funder":[{"DOI":"10.13039\/100000030","name":"Centers for Disease Control and Prevention","doi-asserted-by":"publisher","award":["NU50CK000574"],"award-info":[{"award-number":["NU50CK000574"]}],"id":[{"id":"10.13039\/100000030","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,12,2]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background and objectives<\/jats:title>\n                    <jats:p>New antibiotics effective against carbapenem-resistant Enterobacterales (CRE) provide additional treatment options, but data on clinician decision-making are limited. We sought to understand treatment preferences, factors influencing antibiotic selection for CRE infections and barriers to prescribing newer agents.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We surveyed infectious disease clinicians through the Infectious Diseases Society of America (IDSA) Emerging Infections Network (EIN) about their experience treating CRE infections, availability of resistance mechanism testing, antibiotic choices in four CRE infection scenarios and barriers to using newer antibiotics. We used the 2023 IDSA Guidance on the Treatment of Antimicrobial Resistant Gram-Negative Infections to classify antibiotic selections for the scenario-based questions as preferred approach, alternative option or not in guidance.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Overall, 441 EIN members responded. Among these, 337 (76%) reported treating a CRE infection in the last year. For the clinical scenarios, 851 (63%) of 1356 selections were IDSA-preferred approaches; of these, 653 (77%) were for ceftazidime-avibactam, either alone (n\u200a=\u200a456) or in combination with aztreonam (n\u200a=\u200a197), more than for other \u03b2-lactam\/\u03b2-lactamase inhibitor combination agents active against CRE. For an uncomplicated urinary tract infection caused by carbapenem-resistant Klebsiella pneumoniae, where no preferred approaches were available, the most common antibiotic selected was oral fosfomycin (169\/343 (49%)).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Most clinicians selected antibiotics aligned with the IDSA guidance for serious CRE infections, although the frequent selection of an agent not in the guidance for uncomplicated cystitis suggests that treatment selection is complex and may depend on infection severity, among other factors. The preference for ceftazidime-avibactam among similar agents is notable and may reflect its longer market availability.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/jac\/dkaf371","type":"journal-article","created":{"date-parts":[[2025,9,16]],"date-time":"2025-09-16T11:37:51Z","timestamp":1758022671000},"page":"3335-3339","source":"Crossref","is-referenced-by-count":2,"title":["Treatment preferences by infectious diseases clinicians for carbapenem-resistant Enterobacterales infections"],"prefix":"10.1093","volume":"80","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6872-1216","authenticated-orcid":false,"given":"Samuel E","family":"Cincotta","sequence":"first","affiliation":[{"name":"Division of Healthcare Quality Promotion, U.S. Centers for Disease Control and Prevention , 1600 Clifton Road NE, Atlanta, GA 30329 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Belinda E","family":"Ostrowsky","sequence":"additional","affiliation":[{"name":"Division of Healthcare Quality Promotion, U.S. Centers for Disease Control and Prevention , 1600 Clifton Road NE, Atlanta, GA 30329 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9924-0458","authenticated-orcid":false,"given":"Jessica","family":"Howard-Anderson","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Emory University School of Medicine , 100 Woodruff Circle, Atlanta, GA 30322 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0278-506X","authenticated-orcid":false,"given":"Susan E","family":"Beekmann","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, University of Iowa Carver College of Medicine , 451 Newton Road, Iowa City, IA 52242 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip M","family":"Polgreen","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, University of Iowa Carver College of Medicine , 451 Newton Road, Iowa City, IA 52242 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maroya S","family":"Walters","sequence":"additional","affiliation":[{"name":"Division of Healthcare Quality Promotion, U.S. Centers for Disease Control and Prevention , 1600 Clifton Road NE, Atlanta, GA 30329 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,9,30]]},"reference":[{"key":"2025120206224763300_dkaf371-B1","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1093\/cid\/cit932","article-title":"The Infectious Diseases Society of America Emerging Infections Network: bridging the gap between clinical infectious diseases and public health","volume":"58","author":"Pillai","year":"2014","journal-title":"Clin Infect Dis"},{"key":"2025120206224763300_dkaf371-B2","doi-asserted-by":"publisher","first-page":"ciad428","DOI":"10.1093\/cid\/ciad428","article-title":"Infectious Diseases Society of America 2023 guidance on the treatment of antimicrobial resistant gram-negative infections","author":"Tamma","year":"2023","journal-title":"Clin Infect Dis"},{"key":"2025120206224763300_dkaf371-B3","doi-asserted-by":"publisher","first-page":"559","DOI":"10.7326\/M23-2309","article-title":"Assessing clinician utilization of next-generation antibiotics against resistant gram-negative infections in U.S. hospitals","volume":"177","author":"Strich","year":"2024","journal-title":"Ann Intern Med"},{"key":"2025120206224763300_dkaf371-B4","doi-asserted-by":"publisher","first-page":"ofaf079","DOI":"10.1093\/ofid\/ofaf079","article-title":"New kids on the block: estimating use of next-generation Gram-negative antibiotics across greater than 700 hospitals in the United States","volume":"12","author":"Harris","year":"2025","journal-title":"Open Forum Infect Dis"},{"key":"2025120206224763300_dkaf371-B5"},{"key":"2025120206224763300_dkaf371-B6","author":"Centers for Disease Control and Prevention","year":"2025"},{"key":"2025120206224763300_dkaf371-B7","doi-asserted-by":"publisher","first-page":"e00749-17","DOI":"10.1128\/mBio.00749-17","article-title":"Widespread fosfomycin resistance in gram-negative bacteria attributable to the chromosomal fosA gene","volume":"8","author":"Ito","year":"2017","journal-title":"mBio"},{"key":"2025120206224763300_dkaf371-B8","doi-asserted-by":"publisher","first-page":"e00634-19","DOI":"10.1128\/JCM.00634-19","article-title":"The role of fosA in challenges with fosfomycin susceptibility testing of multispecies Klebsiella pneumoniae carbapenemase-producing clinical isolates","volume":"57","author":"Elliott","year":"2019","journal-title":"J Clin Microbiol"},{"key":"2025120206224763300_dkaf371-B9","doi-asserted-by":"publisher","first-page":"e169","DOI":"10.1093\/cid\/ciaa1478","article-title":"Infectious Diseases Society of America antimicrobial resistant treatment guidance: gram-negative bacterial infections","volume":"72","author":"Tamma","year":"2020","journal-title":"Practice"}],"container-title":["Journal of Antimicrobial Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jac\/article-pdf\/80\/12\/3335\/64440101\/dkaf371.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jac\/article-pdf\/80\/12\/3335\/64440101\/dkaf371.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,2]],"date-time":"2025-12-02T11:22:56Z","timestamp":1764674576000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jac\/article\/80\/12\/3335\/8268716"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,30]]},"references-count":9,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2025,9,30]]},"published-print":{"date-parts":[[2025,12,2]]}},"URL":"https:\/\/doi.org\/10.1093\/jac\/dkaf371","relation":{},"ISSN":["0305-7453","1460-2091"],"issn-type":[{"value":"0305-7453","type":"print"},{"value":"1460-2091","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,12]]},"published":{"date-parts":[[2025,9,30]]}}}